Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 6, 2005, Pages 1096-1103

  Pratt Riccio, Lilian R ^a   Lima Jr , Josué C ^a   Carvalho, Leonardo J M ^a   Theisen, Michael ^b   Espíndola Mendes, Erika C ^a   Santos, Fátima ^c   Oliveira Ferreira, Joseli ^a   Goldberg, Anna C ^d   Daniel Ribeiro, Cláudio T ^a   Banic, Dalma M ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATENS SERUM INSTITUT   (Denmark)

^c FUNDAÇÃO NACIONAL DE SAÚDE   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; EPITOPE; HLA ANTIGEN CLASS 2; MALARIA VACCINE; PLASMODIUM FALCIPARUM GLUTAMATE RICH PROTEIN; UNCLASSIFIED DRUG;

ADULT; AFRICA; AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BRAZIL; ENDEMIC DISEASE; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM;

PLASMODIUM FALCIPARUM;

EID: 29844448455     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.1096     Document Type: Article

References (43)

1. Borre MB, Dziegiel M, Hogh B, Petersen E, Rieneck K, Riley E, Meis JF, Aikawa M, Nakamura K, Harada M, Wind A, Jacobsen PH, Cowland J, Jepsen S, Axelsen NH, Vuust J, 1991. Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the pre-erythrocytic and erythrocytic stages of the vertebrate life cycle. Mol Biochem Parasitol 49: 119-131.
2. Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B, 1995. Antigenicity and immunogenicity of recombinant glutamate-rich protein (GLURP) of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 2: 30-34.
3. Stricker K, Vuust J, Jepsen S, Oeuvray C, Theisen M, 2000. Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 111: 123-130.
4. Dziegiel M, Borre MB, Jepsen S, Hogh B, Petersen E, Vuust J, 1991. Recombinant Plasmodium falciparum glutamate rich protein; purification and use in enzyme-linked immunosorbent assay. Am J Trop Med Hyg 44: 306-313.
5. Boudin C, Chumpitazi B, Dziegiel M, Peyron F, Picot S, Hogh B, Ambroise-Thomas P, 1993. Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso. J Clin Microbiol 31: 636-641.
6. Dziegiel M, Rowe P, Bennett S, Allen SJ, Olerup O, Gottschau A, Borre M, Riley EM, 1993. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun 61: 103-108.
7. Hogh B, Petersen E, Dziegiel M, David K, Hanson A, Borre M, Holm A, Vuust J, Jepsen S, 1992. Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg 46: 307-313.
8. Hogh B, Thompson R, Zakiuddin IS, Boudin C, Borre M, 1993. Glutamate rich Plasmodium falciparum antigen (GLURP). Parassitologia 35: 47-50.
9. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, Jepsen S, Nkrumah FK, Theander TG, Hviid L, 2000. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181: 1202-1205.
10. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P, 2000. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68: 2617-2620.
11. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P, 2004. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72: 247-252.
12. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P. 1998. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 66: 11-17.
13. Khusmith S, Druilhe P, 1983. Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect Immun 41: 219-223.
14. Lunel F, Druilhe P. 1989. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infect Immun 57: 2043-2049.
15. Bouharoun-Tayoun HP, Attanath P, Subchaeron A, Chongsuphajaisiddhi T, Druilhe P, 1990. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
16. Bouharoun-Tayoun HP, Druilhe P, 1992. P. falciparum malaria: evidence for an isotype imbalance may be responsible for the delayed acquisition of protective immunity. Infect Immun 60: 1473-1481.
17. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, Aikawa M, Filgueira MC, Tartar A, Druilhe P, 1994. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
18. Theisen M, Soe S, Jessing SG, Okkels LM, Danielsen S, Oeuvray C, Druilhe P, Jepsen S, 2001. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), target by human antibodies mediating parasite killing. Vaccine 19: 204-212.
19. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP, 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641-648.
20. Braga EM, Carvalho LH, Fontes CJ, Krettli AU, 2002. Low cellular response in vitro among subjects with long-term exposure to malaria transmission in Brazilian endemic areas. Am J Trop Med Hyg 66: 299-303.
21. Ministério da Saúde, Fundação Nacional de Saúde, Brasilia, Brasil, 1997. Informe Epidemiológico do SUS.
22. Camargo LM, dal Colletto GM, Ferreira MU, Gurgel SM, Escobar AL, Marques A, Krieger H, Camargo EP, da Silva LH, 1996. Hypoendemic malaria in Rondonia (Brazil, western Amazon region): seasonal variation and risk groups in an urban locality. Am J Trop Med Hyg 55: 32-38.
23. Shute GT, 1988. The microscpopic diagnosis of malaria. Wernsdorfer WH, McGregor SI, eds. Malaria: Principles and Practice of Malariology. New York: Churchill Livingstone, 781-814.
24. Oliveira-Ferreira J, Pratt-Riccio LR, Arruda M, Santos S, Daniel-Ribeiro CT, Goldberg AC, Banic DM, 2004. HLA class II and antibody responses to circumsporozoite protein repeats of P. vivax (VK210, VK247 and P. vivax-like) in individuals naturally exposed to malaria. Acta Trop 92: 63-69.
25. Olerup O, Zetterquist H, 1992. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39: 225-235.
26. Bunce M, O'Neil CM, Barnardo MCNM, Krausa P, Browning MJ, Morris PJ, Welsh KI, 1995. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46: 355-367.
27. Baur MP, Danilovs JA, 1980. Population analysis of HLA-A, B, C, DR and other genetic markers. Terasaki PI, ed. Histocompatibility Testing, Los Angeles: UCLA Tissue Typing Laboratory, 955-1210.
28. Li CC, 1961. Human Genetics: Principles and Methods. New York: McGraw-Hill Book Company.
29. Carvalho LJ, Daniel-Ribeiro CT, Goto H, 2002. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand J Immunol 56: 327-343.
30. Mahanty S, Saul A, Miller LH, 2003. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol 206: 3781-3788.
31. Moorthy VS, Good MF, Hill AV, 2004. Malaria vaccine developments. Lancet 363: 150-156.
32. Jakobsen PH, Theander TG, Hviid L, Morris-Jones S, Jensen JB, Bayoumi RA, Greenwood BM, Bygbjerg IC, Heegaard PM, 1996. Antibody reactivities to glutamate-rich peptides of Plasmodium falciparum parasites in humans from areas of different malaria endemicity. APMIS 104: 734-740.
33. Camargo LM, Noronha E, Salcedo JM, Dutra AP, Krieger H, Pereira da Silva LH, Camargo EP, 1999. The epidemiology of malaria in Rondonia (Western Amazon region, Brazil): study of a riverine population. Acta Trop 72: 1-11.
34. Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brigido MC, Oeuvray C, Povoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT. 2004. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 59: 363-372.
35. Modiano D, Petrarca V, Sirima BS, Luoni G, Nebie I, Diallo DA, Esposito F, Coluzzi M, 1999. Different response to Plasmodium falciparum in west African sympatric ethnic groups: possible implications for malaria control strategies. Parassitologia 41: 193-197.
36. Modiano D, Chiucchiuini A, Petrarca V, Sirima BS, Luoni G, Roggero MA, Corradin G, Coluzzi M, Esposito F, 1999. Inter-ethnic differences in the humoral response to non-repetitive regions of the Plasmodium falciparum circumsporozoite protein. Am J Trop Med Hyg 61: 663-667.
37. Beck HP, Felger I, Barker M, Bugawan T, Genton B, Alexander N, Jazwinska E, Erlich H, Alpers M, 1995. Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population. Am J Trop Med Hyg 53: 284-288.
38. Banic DM, Goldberg AC, Pratt-Riccio LR, De Oliveira-Ferreira J, Santos F, Gras-Masse H, Camus D, Kalil J, Daniel-Ribeiro CT, 2002. Human leukocyte antigen class II control of the immune response to p126-derived amino terminal peptide from Plasmodium falciparum. Am J Trop Med Hyg 66: 509-515.
39. Johnson AH, Leke RG, Mendell NR, Shon D, Suh YJ, Bomba-Nkolo D, Tchinda V, Kouontchou S, Thuita LW, van der Wel AM, Thomas A, Stowers A, Saul A, Zhou A, Taylor DW, Quakyi IA, 2004. Human leukocyte antigen class II alleles influence levels of antibodies to the Plasmodium falciparum asexual-stage apical membrane antigen 1 but not to merozoite surface antigen 2 and merozoite surface protein 1. Infect Immun 72: 2762-2771.
40. Stephens HA, Brown AE, Chandanayingyong D, Webster HK, Sirikong M, Longta P, Vangseratthama R, Gordon DM, Lekmak S, Rungruang E, 1995. The presence of the HLA class II allele DPB1*0501 in ethnic Thais correlates with an enhanced vaccine-induced antibody response to a malaria sporozoite antigen. Eur J Immunol 25: 3142-3147.
41. Patarroyo ME, Vinasco J, Amador R, Espejo F, Silva Y, Moreno A, Rojas M, Mora AL, Salcedo M, Valero V, Goldberg AK, Kalil J, 1991. Genetic control of the immune response to a synthetic vaccine against Plasmodium falciparum. Parasite Immunol 13: 509-516.
42. Nardin EH, Oliveira GA, Calvo-Calle JM, Castro ZR, Nussenzweig RS, Schmeckpeper B, Hall BF, Diggs C, Bodison S, Edelman R, 2000. Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J Infect Dis 182: 1486-1496.
43. Baird JK, Purnomo, Basri H, Bangs MJ, Andersen EM, Jones TR, Masbar S, Harjosuwarno S, Subianto B, Arbani PR, 1993. Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am J Trop Med Hyg 49: 707-719.